| Property | Value |
|---|---|
| Gene Symbol | LRRTM2 |
| Full Name | Leucine-Rich Repeat Transmembrane Neuronal 2 |
| Chromosomal Location | 5q31.1 |
| NCBI Gene ID | 25845 |
| OMIM ID | 610868 |
| Ensembl ID | ENSG00000162881 |
| UniProt ID | Q9H0Y5 |
| Encoded Protein | LRRTM2 |
| Associated Diseases | Autism Spectrum Disorder, Intellectual Disability, Epilepsy, Schizophrenia |
LRRTM2 (Leucine-Rich Repeat Transmembrane Neuronal 2) is a synaptic adhesion molecule that plays a critical role in excitatory synapse development and function. As one of the most potent synaptogenic proteins in the LRRTM family, LRRTM2 binds to presynaptic neurexins and induces both pre- and postsynaptic differentiation, making it essential for neural circuit assembly[1][2].
Located on chromosome 5q31.1, LRRTM2 is expressed predominantly in the brain, with highest levels in the cerebral cortex, hippocampus, and basal ganglia. The protein functions as a master regulator of excitatory synapse formation, controlling synaptic adhesion, neurotransmitter receptor trafficking, and synaptic plasticity.
Mutations in LRRTM2 have been linked to autism spectrum disorder (ASD), intellectual disability, epilepsy, and schizophrenia, highlighting the importance of proper synaptic adhesion molecules in neurodevelopmental and neuropsychiatric disorders[3][4].
LRRTM2 was discovered alongside other LRRTM family members through bioinformatic screening for leucine-rich repeat-containing proteins expressed in the nervous system. Initial studies characterized LRRTM2 as a potent synaptogenic protein capable of inducing excitatory synapse formation in coculture assays[5].
Key milestones in LRRTM2 research:
| Feature | Details |
|---|---|
| Chromosome | 5q31.1 |
| Strand | Plus strand |
| Exons | 3 |
| Transcript length | ~2.5 kb coding region |
| Protein length | 644 amino acids |
The LRR domain of LRRTM2 contains 6 LRR motifs that form a curved, solenoid-like structure responsible for protein-protein interactions:
| LRR Motif | Position | Function |
|---|---|---|
| LRRNT | N-terminal | Caps the LRR array |
| LRR1-6 | Central | Protein binding interface |
| LRRCT | C-terminal | Stabilizes the LRR fold |
The curved LRR structure provides a large interaction surface for binding to presynaptic partners, particularly the neurexin family of synaptic adhesion molecules.
LRRTM2 binds with high affinity to both alpha- and beta-neurexins[2:1]:
The LRRTM2-neurexin interaction is bidirectional:
LRRTM2 is one of the most potent synaptogenic proteins identified[@soud пря2013]:
| Synaptic Component | Induced by LRRTM2 |
|---|---|
| Synaptic vesicles | Presynaptic clustering |
| Synapsin I | Recruitment |
| VGAT | Inhibitory synapse formation |
| PSD-95 | Postsynaptic scaffold |
| AMPA receptors | Synaptic accumulation |
| NMDA receptors | Functionality |
LRRTM2 participates in several signaling pathways[6]:
LRRTM2 is essential for excitatory (glutamatergic) synapse development[5:1]:
| Developmental Stage | LRRTM2 Function |
|---|---|
| Early development | Initial contact formation |
| Synapse specification | Excitatory vs inhibitory |
| Synapse maturation | Receptor accumulation |
| Synapse maintenance | Long-term stability |
LRRTM2 plays a role in synaptic plasticity[7]:
During development, LRRTM2 guides neural circuit formation[8]:
| Region | Expression Level | Notes |
|---|---|---|
| Cerebral cortex | Very high | Pyramidal neurons |
| Hippocampus | Very high | CA1-CA3, dentate gyrus |
| Basal ganglia | High | Striatal neurons |
| Cerebellum | Moderate | Purkinje cells |
| Thalamus | Moderate | Relay neurons |
| Brainstem | Lower | Various nuclei |
| Developmental Stage | Expression | Function |
|---|---|---|
| Embryonic E14 | Low | Initial specification |
| Postnatal P7 | Peak | Synaptogenesis |
| Postnatal P21 | High | Synapse maturation |
| Adult | Moderate | Synapse maintenance |
LRRTM2 localizes to postsynaptic densities:
LRRTM2 is strongly associated with ASD[3:1][9]:
| Evidence Type | Finding |
|---|---|
| Genetic | Rare de novo variants in ASD patients |
| Expression | Altered expression in ASD brain |
| Functional | Disrupted neurexin binding |
| Model | Knockout mice show social deficits |
LRRTM2 mutations cause non-syndromic intellectual disability:
| Mutation Type | Effect |
|---|---|
| Missense | Reduced synaptogenic activity |
| Nonsense | Truncated protein |
| Frameshift | Loss of function |
LRRTM2 variants have been identified in epilepsy patients:
LRRTM2 is a susceptibility gene for schizophrenia[4:1]:
LRRTM2 represents a therapeutic target:
| Strategy | Approach | Status |
|---|---|---|
| Gene therapy | Restore expression | Preclinical |
| Small molecule enhancers | Increase function | Discovery |
| Cell therapy | Stem cell approaches | Early research |
| Partner | Interaction Type | Functional Consequence |
|---|---|---|
| NRXN1alpha | Ligand | Synapse formation |
| NRXN1beta | Ligand | Synapse formation |
| NRXN2 | Ligand | Synapse formation |
| NRXN3 | Ligand | Synapse formation |
| PSD-95 | Scaffold | Synaptic stabilization |
| GRIP1 | Adaptor | AMPA-R trafficking |
| PICK1 | Adaptor | AMPA-R endocytosis |
| DLGAP1 | Scaffold | Postsynaptic organization |
| Pathway | Modulation |
|---|---|
| Glutamatergic signaling | Synapse specification |
| PI3K/Akt | Survival signaling |
| MAPK/ERK | Differentiation |
| CaMKII | Plasticity |
LRRTM2 knockout mice show[10]:
| Phenotype | Description | Relevance |
|---|---|---|
| Synapse loss | Reduced excitatory synapses | Mechanistic |
| Memory deficits | Impaired LTP | Cognitive |
| Social behavior | Altered social interaction | ASD model |
| Seizure susceptibility | Network hyperexcitability | Epilepsy model |
| Method | Application |
|---|---|
| Immunohistochemistry | Localization |
| Live-cell imaging | Synapse dynamics |
| Biochemistry | Protein interactions |
| RNA-seq | Transcriptome |
| System | Use |
|---|---|
| Knockout mice | Functional studies |
| Knockin mice | Mutation modeling |
| iPSC neurons | Human disease modeling |
| Organoids | Circuit development |
LRRTM2 mutations disrupt multiple aspects of synaptic function[3:2][9:1], contributing to ASD pathophysiology through:
| Mechanism | Effect | Outcome |
|---|---|---|
| Neurexin binding loss | Impaired synapse formation | Reduced connectivity |
| PSD-95 mislocalization | Altered scaffold structure | Synaptic instability |
| AMPA receptor trafficking | Impaired synaptic transmission | Functional deficits |
| Intracellular signaling | Dysregulated downstream pathways | Network dysfunction |
LRRTM2 variants cause non-syndromic intellectual disability through:
| Mutation Class | Molecular Consequence | Phenotype |
|---|---|---|
| Missense (hypomorphic) | Reduced function | Moderate ID |
| Nonsense/truncation | Complete loss | Severe ID |
| Frameshift | Null allele | Severe ID |
| Splice site | Reduced expression | Variable |
LRRTM2 variants contribute to epilepsy through:
| Seizure Type | LRRTM2 Mechanism |
|---|---|
| Generalized tonic-clonic | Network synchronization |
| Absence | Thalamocortical circuits |
| Focal | Cortical hyperconnectivity |
| Myoclonic | Motor cortex hyperexcitability |
LRRTM2 restoration strategies[@soud пря2013]:
| Strategy | Delivery | Status |
|---|---|---|
| AAV-LRRTM2 | Stereotactic injection | Preclinical |
| CRISPR activation | Viral vector | Discovery |
| mRNA delivery | Nanoparticles | Research |
Drug-like molecules targeting LRRTM2:
| Family Member | Brain Expression | Synaptic Localization |
|---|---|---|
| LRRTM1 | High (cortex, hippocampus) | Postsynaptic |
| LRRTM2 | Very high (ubiquitous) | Postsynaptic (excitatory) |
| LRRT3 | Moderate (cortex) | Postsynaptic |
| LRRT4 (LGI2) | Variable | Presynaptic |
| Kinase | LRRTM2 Effect | Functional Outcome |
|---|---|---|
| CaMKII | Phosphorylation | Activity-dependent modulation |
| PKA | Phosphorylation | Synaptic plasticity regulation |
| PKC | Phosphorylation | Internalization control |
| Src | Phosphorylation | Activity enhancement |
LRRTM2 involvement in AD:
Potential LRRTM2 roles in PD:
| Application | Available Tools |
|---|---|
| Western blot | Anti-LRRTM2 (multiple vendors) |
| IHC | Validated antibodies |
| IP | Tagged constructs |
| ELISA | Quantification kits |
| Model | Use |
|---|---|
| Lrrtm2 KO | Phenotypic characterization |
| Lrrtm2 KI (patient mutation) | Disease modeling |
| Reporter (GFP/mCherry) | Expression tracking |
| Cre-inducible | Conditional KO |
Linhoff et al. LRRTM1 and LRRTM2 as neurexin ligands. 2009. ↩︎
Ko et al. LRRTM2-neurexin interaction and synaptogenesis. 2011. ↩︎ ↩︎
Dickerson et al. LRRTM2 mutations in ASD. 2013. ↩︎ ↩︎ ↩︎
Uchida et al. LRRTMs in psychiatric disorders. 2016. ↩︎ ↩︎
Shooter et al. LRRTMs and synaptogenesis. 2012. ↩︎ ↩︎
Lin et al. LRRTM2 signaling mechanisms. 2022. ↩︎
Boer et al. LRRTM2 and synaptic plasticity. 2018. ↩︎
Thor et al. LRRTM2 in neural circuit development. 2023. ↩︎
Medley et al. LRRTM2 variants in neurodevelopment. 2017. ↩︎ ↩︎
Hayashi et al. LRRTM2 knockout phenotypes. 2014. ↩︎